Streck, Inc., has added markers to CD-Chex CD117 Plus, a positive procedural control for CD117, and now, CD25 and CD71. According to company representatives, CD-Chex 117 Plus eliminates the need for laboratories to hold and validate patient samples to use as a control for CD117, CD25, and CD71, saving time and money.
CD-Chex CD117 Plus was developed with characteristics similar to the abnormal peripheral blood leukocytes often found in a hematolymphoid neoplastic patient sample. It possesses surface CD117, CD25, and CD71 that are detectable with fluorescent monoclonal antibodies by flow cytometry. Abnormal leukocytes are distinguishable from normal leukocytes on the basis of light scatter properties and a low level of CD45 expression. CD-Chex CD117 Plus features 30-day open-vial stability and 90-day closed-vial stability. It is For Research Use Only; not for use in diagnostic procedures.
Streck also offers CD-Chex Plus, a positive procedural control for monitoring immunophenotyping by flow cytometry. It provides assayed CD markers on a single control, including those on the HIV panel of markers and a normal level of CD34+ cells. CD-Chex Plus is manufactured from normal human peripheral blood leukocytes and erythrocytes and is available in two clinically relevant levels of CD4+ cells. Learn more about CD-Chex CD117 Plus, the new markers, and related products.
Read more
